Congenital muscular dystrophy (CMD) is a heterogeneous group of inherited neuromuscular disorders characterized by severe muscle weakness, ocular and neuronal migration abnormalities, and variable mental retardation (1) . Within recent years, it has become increasing clear through genetic studies that hypoglycosylation of the protein dystroglycan (DG) is a commonality in many forms of CMD (the so-called dystroglycanopathies). DG is post-translationally cleaved into an extracellular α -DG subunit and a transmembrane β-DG subunit (2). α -DG is a key component of the dystrophin-glycoprotein complex (DGC) that serves as a link between the cytoskeleton of cells and the extracellular matrix by binding to proteins such as laminin (3) . Interaction between α -DG and its extracellular ligands require α-DG to be properly posttranslationally modified through the addition of Olinked oligosaccharides, specifically O-mannose (4, 5) . To date, mutations in six genes that encode determined or predicted glycosyltrasferases have been shown to result in varying forms of CMD in which the post-translational processing of α-DG is affected (4) (5) (6) . The six mutated genes and their original resulting form of CMD are: protein Omannosyltransferase 1(POMT1) and 2 (POMT2)-Walker-Warburg Syndrome (WWS) (7, 8) , protein O-linked mannose β1,2 Nacetylglucosaminyltransferase (POMGnT1)-Muscle-Eye-Brain disease (MEB) (9) , FukutinFukuyama congenital muscular dystrophy (FCMD) (10) , Fukutin-related protein (FKRP)-congenital muscular dystrophy 1C (MDC1C) (11), and LARGE-congenital muscular dystrophy 1D (MDC1D) (12) . Recent work has demonstrated that selected mutations in some of these genes can cause various forms of CMD likely dependent on the severity of the mutation on enzymatic activity and stability (13) . Abnormal glycosylation of α-DG appears to be a commonality among all of the aforementioned forms of CMD. While expression of α-DG appears to not be grossly affected, the ability of α-DG to be recognized by monoclonal antibodies IIH6 and VIA4 1 is eliminated, as well as the ability of α-DG to properly bind its ligands (14) .
α−DG is comprised of a central mucin-like region which is extensively heterogeneously glycosylated with glycan chains that are initiated by both O-GalNAc and O-mannose (15) (16) (17) . POMT1 and 2 and POMGnT1 have been shown to catalyze the first two steps involved in the synthesis of a sialyated O-mannosyl tetrasaccharide structure (9, 18) . The previously identified glycan structure, Neu5Ac(α2-3)Gal(β1-4)GlcNAc(β1-2)Man, was identified on α-DG isolated from both brain and muscle and was previously thought to be required for ligand binding activity. However, more recent studies have suggested that laminin binding is most likely not dependent on this structure, as treating α-DG with a series of glycosidases resulting in the trimming of this O-mannosyl tetrasaccharide structure does not abolish laminin binding activity, but rather enhances the ability of α-DG to bind to laminin (19) .
Additionally, recent work by Yoshida-Moriguchi et. al., has shown that LARGE, a putative glycosyltransferase, is involved in the synthesis of a rare extended phosphorylated O-mannosyl trisaccharide core structure on recombinant α-DG secreted from HEK293H cells, that is required for laminin binding (20) . The roles that the other putative glycosylatransferases, fukutin and FKRP, have in the post-translational processing of α-DG have yet to be determined.
Given the importance of post-translational processing of α-DG as related to CMD and the abundance of O-mannosyl glycan structures in the brain (~30% of O-glycan structures are Omannose initiated (21)), we sought to identify and characterize the relative abundance of O-glycan structures released from the mouse brain proteins of CMD disease models and their comparative wild type controls. To do this we implemented strategies that had been previously developed and described (22) . Glycomic analysis of the various mouse models of CMD consisted of chemically releasing all O-glycans by reductive β-elimination, followed by permethylation and analysis by tandem mass spectrometry (23) . From the implemented workflow we were able to fully characterize many O-glycans released from mouse brain proteins of selected mouse models of CMD and compare their relative abundances between the control and disease states. This study highlights the relative abundance of O-mannose and OGalNAc initiated glycan structures characterized from the three CMD mouse brain models studied as well as the role of crucial enzymes and substrates in the O-mannosylation process.
EXPERIMENTAL PROCEDURES Preparation of whole animal and tissue specific knockout mouse models of CMD-
The whole body and tissue specific knockout mouse models of congenital muscular dystrophy were prepared as reported previously for POMGnT1, Large (myd), and GFAP-DAG1 (24) (25) (26) . Preparation of Brain Protein PowderProtein powder was prepared from the brains of various mouse models (day P2-P7) of congenital muscular dystrophy as described previously (23) . Briefly, to prepare protein powder from mouse brains, frozen brains were homogenized and delipidated in a solvent mixture with a final ratio of chloroform/methanol/water equal to that of 4:8:3. The extracted material was allowed to incubate for 6 hours at room temperature. The precipitated protein material was collected by centrifugation, and the resulting protein pellet was re-extracted with fresh solvent. The precipitated protein pellet was washed with ice cold 20% acetone and then dried under a gentle nitrogen stream at 45ºC.
Release of O-linked Glycans-
O-glycans were released using reductive β-elimination as reported previously (16) . Briefly, protein powder was resuspended with 1M NaBH 4 in 50mM NaOH and incubated at 45°C for 18 hrs. Following incubation, the reaction mixture was neutralized by adding 10% acetic acid dropwise while vortexing.
The completely neutralized samples were desalted by loading onto an AG-50W-X8 (Bio-Rad) column (1mL bed volume). The released oligosaccharides were eluted from the column with 3 volumes of 5% acetic acid and dried to dryness using a SpeedVac. Borate was removed by adding 10% acetic acid in methanol and drying under a nitrogen stream at 45°C. All comparative analysis was conducted on equal amounts of protein.
Permethylation and Analysis Of O-glycans by NanOspray Ionization Mass Spectrometry (NSI-MS
n )-Released oligosaccharides were permethylated to facilitate their analysis by mass spectrometry as reported previously (27) . For analysis by NSI-MS n , permethylated glycans were dissolved in 1mM NaOH in 50% methanol and directly infused into a linear ion trap mass spectrometer (LTQ, Thermo Scientific) at a flow rate of 0.4 mL/min. As described previously, the total ion mapping (TIM) function of the Xcallibur software package was used to detect and quantify the prevalence of all detected glycan structures (22) . Through the application of TIM, MS/MS spectra were acquired within overlapping collection windows that span 2.8 mass units. This method was used to scan the m/z range from 200 to 2000. Following characterization of the Oglycan structures observed from the resulting TIM scan, the relative abundance of either individual glycans or group of isobaric glycans were determined.
The relative abundance of the observed glycan structures was calculated based upon peak area from a single glycan structure relative to the total area of all observed O-glycan structures. The analysis of O-glycans released from both the POMGnT1 +/+ and -/-as well as the LARGE +/+ and -/-were performed in triplicate and differences in the relative abundance of these glycan structures is indicated, while α-DG +/+ and -/-(GFAP-cre DAG1 knockout) were only performed in duplicate and the average value without standard deviation is shown. Glycan nomenclature and representation of all glycan structures shown in figures and tables is in agreement with the guidelines proposed by the consortium of functional glycomics with unidentified HexNAc residues displayed in grey. Characterization of O-mannitol by High-Pressure Liquid ChromatographyAs described previously (23) , monosaccharides were released from both POMGnT1 +/+ and -/-mouse brain proteins and the abundance of Omannitol was analyzed as described previously (23) . Briefly, O-glycans were released from protein powder prepared from both POMGnT1 +/+ and -/-brains by reductive β-elimination, which were separated on a Dionex CarboPac MA-1 column (250 X 4 mm) and detected by HPAEC-PAD. The detected monosaccharide peaks were later quantified based on monosaccharide alditol standards (note that glucitol levels are inherently difficult to measure by this method (23)). Western BlottingMouse brain proteins from all three phenotypes were separated by SDS-PAGE on a 7.5% Tris-HCl precast gel purchased from Bio-Rad Laboratories. Following separation proteins were transferred to PVDF membranes using semi-dry transfer and probed using monoclonal antibody IIH6 (1:2000 dilution) (Millipore) and ERK-2 (C-14) (1:5000 dilution) (Santa Cruz) as a loading control. Proteins were detected using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific). o C to cleave the Ac-YVEPT(Ac 4 -α-D-Man)AV-NH 2 from the resin, and concurrently remove t Bu and O t Bu sidechain protecting groups. The cleaved peptide-resin mixture was then washed extensively with TFA (3×1 ml), and the O-acetylated glycopeptide was precipitated by adding cold anhydrous ether (100 ml) to the combined filtrates. The ether-treated material was kept overnight at 4 o C, and was then collected by centrifugation and washed further with cold ether (2×10 ml). The O-acetylated glycopeptide was purified by semi-preparative RP-HPLC, and the fractions with the desired products were pooled and lyophilized. The lyophilized Oacetylated glycopeptide was then dissolved in methanol (~4 ml/mg) for removal of O-acetyl groups. The pH of the methanol solution was adjusted to ~9 (as detected by wet litmus paper) by adding a solution of NaOMe in methanol. The Odeacetylation reaction was carried out with mild stirring, and monitored by analytical RP-HPLC, going to completion after 5 h. Powdered CO 2 (dry ice) was then added carefully to reach a pH of 6, and the pure glycopeptide was obtained after semipreparative RP-HPLC followed by lyophilization of the appropriate fractions. Amount: 15 mg. Overall yield based on initial substitution of resin:
Synthesis of Ac
was prepared from Ac-YVEP(Man-α)TAV-NH 2 using the POMGnT1 enzyme. The DNA sequence for human POMGnT1 (provided by Dr. Huaiyu Hu, State University of New York) was cloned into a pSecTAG2B vector and stably transfected into HEK-293 cells. For POMGnT1 purification, culture media was collected from the HEKPOMGnT1 cells and combined with a mixture of protease inhibitors. The media were then chromatographed through a Nickel chelating column and the active glycosyltransferase was partially purified by elution with 300 mM imidazole at pH of 6.8. To avoid aggregation and stabilize the recombinant enzyme in solution, bovine serum albumin was usually added and the resulting mixture was dialyzed (to remove the imidazole), and then concentrated. To assay the enzyme activity, the incorporation of radiolabeled GlcNAc from UDP-[
3 H]-GlcNAc into Manα1-Obenzyl was measured over time and the reaction product was purified by solid phase extraction on a SepPack C-18 cartridge . In a typical purification procedure, 2 to 5 mL of a solution with partially pure enzyme could be obtained with an activity of 190 milliunits/mL. 0.8 mg of Ac-YVEP(Man-α-)TAV-NH 2 was treated with recombinant POMGnT1 and UDP-GlcNAc and the process driven to completion over 72 hours using buffer conditions as previously described in the presence of alkaline phosphatase to remove to prevent the accumulation of the glycosyltransferase inhibitor UDP. The monosaccharide and disaccharide substituted peptides were separated by analytical RP-HPLC on a C 18 column (4.6×250 mm), with detection at 220 nm, and elution with 0.1% aq. TFA (buffer A)-0.1% TFA in CH 3 CN (buffer B), linear gradient from 0 to 10% buffer B, at a flow rate of 1 ml/min for 40 min. NMR Studies-A sample of < 1mg of Ac-YVEP(GlcNAc-β-1,2-Man-α-)TAV-NH 2 was dissolved in 90µL of D 2 O in a 3mm Shigemi NMR microcell (Shigemi, Inc., Allison Park, PA). NMR spectra were obtained on a Varian NMRS 600 MHz NMR spectrometer with a 3mm HCN coldprobe. 1 1A and B) allowed for the detection of O-glycan structures released from both POMGnT1 +/+ and -/-mouse brain proteins. The structural assignment of O-glycans observed in the full MS scans was based upon subsequent MS/MS fragmentation data. In order to detect all of the released Oglycan structures, we used total ion mapping (TIM) methodologies as previously described (22) . By using TIM, we were able to acquire MS/MS fragmentation profiles allowing for the detection of O-glycans over the entire scanned m/z range. In Figure 1C and D, we show the MS/MS fragmentation profile of disialylated T antigen (m/z 1256) detected in both the POMGnT1 +/+ and -/-. Table 1 contains a list of all glycan structures detected in both the POMGnT1 +/+ and -/-. Fragmentation of extended O-mannose structures was not observed in the POMGnT1 -/-(the glycan prevalence is indicated as 'ND' (not detected) in Table 1 for all extended O-mannose structures). Additionally, mouse brain proteins from both POMGnT1 +/+ and -/-were separated by SDS-PAGE and probed with monoclonal antibody IIH6 (Fig. 1E) , which detects fully glycosylated, functionally active α-DG. From the Western blot we observed a loss of reactivity of IIH6 with proteins from the POMGnT1 -/-, indicating that α-DG is hypoglycosylated and no longer functionally active. Through HPAEC-PAD analysis of β-eliminated, reduced monosaccharide alditols from both POMGnT1 +/+ and -/-mouse brain proteins (equal amounts based on protein content), Man-ol was shown to be elevated ~2.4 fold in the POMGnT1 -/-compared to the POMGnT1 +/+ littermate control suggesting that POMT1/2 activity was unaffected (Fig. 1F) .
As GlcNAc extension on O-mannose has recently been observed on α-DG in a β1-4 linkage (20), we wanted to confirm the previous work by others that had demonstrated that POMGnT1 extends O-mannose in a β1-2 linkage. Thus, we used recombinant POMGnT1 and UDP-GlcNAc to extend a syntethic O-mannose peptide and following purification by RP-HPLC analyzed the peptide by NMR techniques. The assignments of the resonance positions for all NMR 1 H and 13 C signals arising from the GlcNAc-Man disaccharide glycan on the glycopeptide Ac-YVEP(GlcNAc-β-1,2-Man-α-)TAV-NH 2 (residues 410-416 of αDG), prepared by recombinant POMGnT1 enzymatic addition of GlcNAc to the Man glycopeptide, were made using homonuclear twodimensional 1 H DQ-COSY, and TOCSY experiments and heteronuclear 1 H-13 C HMQC and HMBC two-dimensional correlations. The latter experiment shows correlations between 1 H and 13 C nuclei with two or three intervening bonds (28) allowing explicit connections to be established across the glycosidic linkages. The initial identification of the Man-α and the GlcNAc-β anomeric sites could be readily made based on the distinct 1 H and 13 C carbon shift positions associated with their respective stereochemistry (29, 30) . Further, the 3 J H1-H2 couplings for the anomeric protons were as predicted for the linkage stereochemistry, with a large coupling ~ 8.5Hz in the 1 H 1-dimensional spectrum clearly showing the GlcNAc linkage to be β (30) . The location of the Man anomeric signals were also in agreement with that observed for the synthetic substrate glycopeptide Ac-YVEP(Man-α)TAV-NH 2 (data not shown). Using correlations that could be traced back to the assigned anomeric resonances, shifts for nuclei at the additional sites in each residue were determined with information derived from the experiments above (Supplemental Figures and  Table) . Based on these assignments, HMBC cross peaks arising from 1 H and 13 C connectivities in both directions across the glycosidic linkages between the sugar residues, and from the Man to the Thr β (Fig. 2) were identified. These results unequivocally establish the formation of a β1-2 linkage between the GlcNAc and the Man residues mediated by POMGnT1.
O-glycans released and detected from LARGE +/+ vs. -/-are identical-
O-linked glycans were released from LARGE +/+ and -/-(myd1) mouse brain proteins as described previously. Full MS scans (m/z 700-1500) ( Fig.  3A and B) of the released O-glycans indicate that the most abundant glycan structures found in both the LARGE +/+ and -/-samples to be similar. Structural analysis of the released O-glycans was based upon the acquired MS/MS fragmentation data. In Figure 3C and D, we show that synthesis of the O-mannosyl tetrasaccharide structure remains unaffected in the LARGE -/-based upon structural assignment of characteristic fragments. Prevalence of all the characterized glycan structures were quantified by using TIM and no statistically relevant changes were observed (Table  2) . Mouse brain proteins from both LARGE +/+ and -/-were separated by SDS-PAGE and probed with monoclonal antibody IIH6 (Fig. 3E) . From the Western blot we observed a loss of reactivity of IIH6 with proteins from the LARGE -/-, indicating that α -DG is hypoglycosylated and no longer functionally active. O-mannose initiated glycan structures are still detectable in the α-DG -/-brainAs previously described O-glycans were released from α-DG +/+ and -/-(GFAP-cre DAG1) mouse brain proteins. Full scans were acquired (m/z 700-1500) of released O-glycans from both α-DG +/+ and -/-mouse brain proteins with the most abundant glycan structures shown (Fig. 4A and B) . Through the MS/MS fragmentation spectra we were able to confirm the presence of a fucosylated O-mannose trisaccahride isolated from the mouse brain proteins of both the α-DG +/+ and -/- (Fig.  4C and D) . Mouse brain proteins from both LARGE +/+ and -/-were separated by SDS-PAGE and probed with monoclonal antibody IIH6 (Fig.  4E) . From the Western blot we observed a substantial loss of reactivity of IIH6 with proteins from the α -DG -/-, indicating the absence of functionally active α-DG. Presumably, the weak band present in the knockout results from endothelial, smooth muscle, and/or other nonneuronal cells in the brain tissue where the dystroglycan gene would still be present and expressed in the neural-specific knockout animal used. DISCUSSION Hypoglycosylation of α-DG through genetic mutations, has been shown to result in various phenotypes of CMD in which the posttranslational processing of α-DG is affected, preventing binding to proteins of the ECM such as laminin, perlecan, and agrin (31) . Proper glycosylation of α-DG is also essential for it to serve as a receptor for lymphocytic choriomeningitis virus (LCMV), Lassa fever virus (LFV), and clade C New World arenaviruses (32, 33) . To date, quantitative comparative studies of O-glycans released from models of CMD have yet to be conducted. Thus we sought to characterize and quantify the structure and prevalence of the various O-glycans released from mouse brain proteins of three models of CMD.
O-glycans were chemically released from the mouse brain proteins of POMGnT1 -/-, LARGE-/-, and α-DG -/-brains as well as their comparative wild type littermates by reductive β-elimination. We started by comparing the full MS scans of O-glycans released from knockout mouse brain to that of their wild type littermates (Fig. 1A,  1B, 3A, 3B, 4A, 4B) . Previous studies have shown that mutations in POMGnT1 prevent the extension of O-mannosyl glycans with GlcNAc residues (34). We were able to confirm the absence of extended O-mannosyl glycans in the POMGnT1 -/-as shown in Table 1 . Interestingly, no β-1-6 branching was observed either suggesting that the activity of POMGnT1 precedes and is necessary for the activity of GnTV-b that is involved in branching of O-mannose structures (35) . However, the presence of OMannitol was elevated approximately 2.4 fold in the brain tissue of the POMGnT1 -/-over that of the POMGnT1 +/+ suggesting no defect in POMT1/2 activity. Structural assignment made based upon acquired MS/MS fragmentation spectra further suggested that O-GalNAc initiated glycans were unaffected (Fig. 1C and D) . Using IIH6 antibody, which specifically recognizes functionally active, fully glycosylated α-DG, we detected the absence of functional α-DG in the POMGnT1 -/-brain as expected.
Although POMGnT1 had previously been reported to extend O-mannosyl glycans with a β1,2 linked GlcNAc residue (36) , the presence of O-mannosyl glycans on α-DG extended with β-1,4 GlcNAc has been recently proposed (20) . Prior work completed to determine the linkage of the GlcNAc concluded that the GlcNAc residue was linked to the C2 position of the mannose based upon treatment of released glycans with jack bean β-N-acetylhexosaminidase which cleaves at the β-1,2 linkage. Additionally, analysis by reversed phase HPLC was used to confirm the extension of the O-mannose by β-1,2 linked GlcNAc (9). However, recent work by Yoshida-Moriguchi et al., indicates the presence of a novel phosphorylated structure in which the O-mannose is extended by a β-1,4 linked GlcNAc (20) . Therefore we definitively determined the linkage at which GlcNAc was added to a synthetic Omannosyl peptide with recombinant POMGnT1 using NMR. From our analysis we concluded the POMGnT1 is indeed responsible for extending Omannose with a β-1,2 linked GlcNAc (Fig. 2) as previously reported (36) . This suggests that there is a yet undetermined GlcNAc transferase capable of acting on O-mannose residues to introduce a β-1,4 linked GlcNAc moiety. Identification of the gene encoding this enzymatic activity could aid in diagnosing CMD patients since a majority have no established genetic etiology.
Our analysis of O-glycans released from LARGE +/+ and -/-mouse brain proteins was unable to detect any differences in the relative abundance of observed O-glycan structures. However, previous work has shown α-DG to be hypoglycosylated in the LARGE deficient myodystrophy (Large myd ) mouse, resulting in a reduction in ligand binding activity (14) . In work previously reported by Sutton-Smith et. al., Oglycan profiles from both a normal and Large myd mouse brain were compared. In their study, they observed 3 O-GalNAc and 2 O-mannose initiated glycan structures of similar abundance in both the normal and Large myd mouse brains (37) . Here, we corroborate their findings with more in depth analysis with our assignment of 25 O-GalNAc structures and 9 O-mannose structures in both the LARGE +/+ and -/-brains with similar abundances. Recently, Campbell and colleagues observed a phosphorylated O-mannosyl glycan structure, which is LARGE dependent, present on α-DG that is required for laminin binding (20) . However, during our analysis of O-glycans released from LARGE -/-mouse brain proteins we were unable to observe this glycan structure (a phosphorylated trisaccharide). Most likely the absence of this glycan structure in the LARGE -/-brains can be attributed to its minor contribution to the complete pool of O-glycans and perhaps may reflect that it is on a limited set of proteins that includes α-DG. In wildtype animals, we would expect for this mannose phosphorylated trisaccharide to be extended from the phosphate with an unknown moiety (20) and, as expected, were unable to detect it during our analysis.
Having fully characterized O-glycans from two mouse models of CMD, we proceeded to characterize O-glycans released from α-DG +/+ and -/-mouse brain proteins, since α-DG is the primary protein substrate associated with CMD and the only well characterized O-mannose modified mammalian protein. Similar to the other instances in which we analyzed the released Oglycans, we proceeded to compare the relative abundance of O-glycans detected from both the wild type and knockout mouse brain proteins. Notably, from the generated full MS scans (Fig. 4  A and B) , there was not a discernable difference in the prevalence of O-mannose initiated glycan structures (Table 3 ) observed in the α-DG -/-brain compared to those detected from the wild type. The presence of O-mannosyl glycans was further confirmed upon analysis of the MS/MS fragmentation spectra as shown in Figures 4 C and  D, where the presence of a fucosylated Omannosyl glycan was confirmed in both the wild type and α-DG -/-brain. Consequently, we observed a significant reduction in the amount of α-DG detectable by western blotting with IIH6 against proteins from the α-DG -/-brain (Figure 4 E). Our results mimic those that were obtained by Campbell and colleges where minute amounts of α-DG (less than 5% wildtype levels) could be detected in the vascular smooth muscle of cerebral blood vessels in the α-DG -/-whole brain extract given that knock-out of the floxed DAG1 gene was facilitated by breeding with GFAP-Cre animals (26) . Comparison of the relative amounts of O-mannosyl glycans expressed on α-DG +/+ and -/-mouse brain proteins resulted in an inability to detect a significant difference in the amount of O-mannose structures attached to brain proteins though α-DG expression was greatly reduced. This is strong evidence for the presence of additional O-mannose modified proteins in the mammalian brain to account for O-mannose initiated structures accounting for ~1/3 of all the O-glycans released from proteins in brains from α-DG -/-mice.
In conclusion, we were able to develop and implement workflows that allowed us to perform glycomic analysis on O-glycans released from the mouse brain proteins from select mouse models involved in O-mannosylation. Collectively, we were able to fully characterize 34 different glycan structures from the three phenotypes and the wildtype controls we investigated (Tables 1, 2, and 3 ). Through our analysis we were able to identify 9 O-mannose and 25 O-GalNAc (including 6 isobaric species) initiated O-glycan structures. It should be noted, by comparing Tables 1-3 , that the percentage of various glycan structures change among the various wildtype controls which likely reflects slight differences in mouse strains, age at analysis, and environments. By characterizing these Oglycan structures, we are able to provide some insight into the role of the known and putative glycosyltransferases POMGnT1 and LARGE, respectively, have on the O-mannosyltion pathway including providing conclusive evidence that POMGnT1 is essential for β1-2 extension of OMan with GlcNAc. Additionally, through the detection of O-mannosyl glycan structures in the α-DG -/-, we were able to provide conclusive evidence for additional O-mannosylated proteins being present in the mammalian brain. 
